

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Imbach *et al.*

Patent No.: 6,875,751

Issued: April 5, 2005

Serial No.: 09/883,033

Filed: June 15, 2001

For: 3'-PRODRUGS OF 2'DEOXY- β -L-NUCLEOSIDES

Attorney Docket No: 06171.105026 (IDX 1005)
(New Docket No. 11874-012-999)



REQUEST TO CHANGE ATTORNEY DOCKET NUMBER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please change the Attorney Docket Number of the above-captioned application from 06171.105026 (IDX 1005) to **11874-012-999**.

Respectfully submitted,

Date: July 31, 2007


Rahul Pathak 42,983
Anthony M. Insogna (Reg. No. 35,203) (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of: Imbach *et al.*

Patent No.: 6,875,751

Issued: April 5, 2005

Serial No.: 09/883,033

Filed: June 15, 2001

For: 3'-PRODRUGS OF 2'DEOXY- β -L-NUCLEOSIDES

Attorney Docket No: 06171.105026 (IDX 1005)
(New Docket No. 11874-012-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

IDENIX PHARMACEUTICALS, INC. (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:



Applicant/Inventor



Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)



IDENIX PHARMACEUTICALS, INC. states that it is, along with Centre National De La Recherche Scientifique ("CNRS") and L'Universite Montpellier II ("UMII"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited, which was recorded in the United States Patent and Trademark Office on September 13, 2001, at Reel 012162, Frame 0351.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII, which was recorded in the United States Patent and Trademark Office on June 6, 2002, at Reel 012962. Frame 0712.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: IDENIX PHARMACEUTICALS, INC.

Date:

April 9, 2007

Signature:

A handwritten signature in black ink, appearing to read "JP Sommadossi", written over a horizontal line.

Typed Name:

Position/Title:

**JEAN-PIERRE SOMMADOSSI, Ph.D.
CHAIRMAN AND CEO
IDENIX PHARMACEUTICALS, INC.**

DV 85256 - 01
IDENIX



16 AVR. 2007

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Imbach *et al.*

Patent No.: 6,875,751

Issued: April 5, 2005

Serial No.: 09/883,033

Filed: June 15, 2001

For: 3'-PRODRUGS OF 2'DEOXY- β -L-NUCLEOSIDES

Attorney Docket No: 06171.105026 (IDX 1005)
(New Docket No. 11874-012-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (assignee) hereby
revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States
Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

- ☐ Applicant/Inventor
☒ Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

.D.V. 85256-01

IDENIX

Revocation and Power of Attorney
U.S. Patent No. 6,875,751
Page 2



STATEMENT UNDER 37 C.F.R. 3.73(b)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ("CNRS") states that it is, along with Idenix Pharmaceuticals, Inc. and L'Université Montpellier II ("UMII"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited, which was recorded in the United States Patent and Trademark Office on September 13, 2001, at Reel 012162, Frame 0351.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII, which was recorded in the United States Patent and Trademark Office on June 6, 2002, at Reel 012962, Frame 0712.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Date: 12 AVR. 2007

Signature: _____

Typed Name: _____

Position/Title: _____

Directeur du Service du Transfert de
Technologies

Frédéric FOUBERT



Directeur de la Politique Industrielle

Marc J. LEDOUX



POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Imbach *et al.*

Patent No.: 6,875,751

Issued: April 5, 2005

Serial No.: 09/883,033

Filed: June 15, 2001

For: 3'-PRODRUGS OF 2'DEOXY- β -L-NUCLEOSIDES

Attorney Docket No: 06171.105026 (IDX 1005)
(New Docket No. 11874-012-999)

**REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

L'UNIVERSITE MONTPELLIER II (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number **20583**

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence addressed for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of less than the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

STATEMENT UNDER 37 C.F.R. 3.73(b)

L'UNIVERSITE MONTPELLIER II ("UMII") states that it is, along with Idenix Pharmaceuticals, Inc. and Centre National De La Recherche Scientifique ("CNRS"), is co-assignee of the patent application/patent identified above by virtue of a chain of title from the inventor(s), to the current assignees as shown below:

1. Inventors Gilles Gosselin and Jean-Louis Imbach assigned their interest to CNRS and inventor Martin L. Bryant assigned his interest to Novirio Pharmaceuticals Limited, which was recorded in the United States Patent and Trademark Office on September 13, 2001, at Reel 012162, Frame 0351.
2. CNRS assigned its interest received from inventor Jean-Louis Imbach to UMII, which was recorded in the United States Patent and Trademark Office on June 6, 2002, at Reel 012962, Frame 0712.
3. The change of name from Novirio Pharmaceuticals Limited to Idenix Pharmaceuticals, Inc. was recorded in the United States Patent and Trademark Office on August 19, 2002, at Reel 013193, Frame 0841, and a Certificate of Domestic Incorporation in Delaware was recorded on February 6, 2003, at Reel 013718, Frame 0543.


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: L'UNIVERSITE MONTPELLIER II La Vice-Présidente
du Conseil Scientifique

Date:

April 17th, 2007

Signature:




Danièle HERIN

Typed Name:

JEAN-LOUIS CUV

Position/Title:

PRESIDENT





UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

NOVEMBER 19, 2001

PTAS

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GEORGIA 30303-1763



101848298A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 09/13/2001

REEL/FRAME: 012162/0351
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

GOSSELIN, GILLES

DOC DATE: 07/16/2001

ASSIGNOR:

IMBACH, JEAN-LOUIS

DOC DATE: 07/17/2001

ASSIGNOR:

BRYANT, MARTIN L.


DOC DATE: 07/16/2001

ASSIGNEE:

NOVIRIO PHARMACEUTICALS LIMITED
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

ASSIGNEE:

CENTRE NATIONAL DA LA RECHERCHE
SCIENTIFIQUE
3, RUE MICHEL-ANGE
75794, PARIS, CEDEX 16, FRANCE



012162/0351 PAGE 2


SERIAL NUMBER: 60212100
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

MARCUS KIRK, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



09-19-2001



06171.105012

FORM-PTO-1595
1-31-92

TRAN

101848298
PATENTS ONLY

ORDINATION

Atty. Docket 06171.105012

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Gilles Gosselin, Jean-Louis Imbach, and Martin L. Bryant

Additional name(s) of conveying party(ies) attached?

☐ Yes☒ No

09/13/01

2. Name and address of receiving party(ies):

Name: Novirio Pharmaceuticals LimitedForeign Address: c/o Walker Secretaries, Walker House, Mary Street, Grand Cayman, Cayman IslandsDomestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☒ Yes☐ No

3. Nature of Conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name

Other _____

Execution Date: 7/16/01, 7/17/01, and 7/16/01

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 60/212,100

B Patent Registration No. (s)

09/883,033Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-5100

6. Number of applications and patents involved:

two7. Total fee (37 CFR 3.41): \$ 80☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.

Sally Sexton

Name of Person Signing

Signature

September 10, 2001

Date

Total number of pages comprising cover sheet: 8

09/18/2001 TDIAZ1 00000106 60212100

01 FC:581

80.00 00

06171.105012

Second Applicant:

CENTRE NATIONAL DA LA RECHERCHE SCIENTIFIQUE
3, Rue Michel-ange
75794, Paris, cedex 16, France

ASSIGNMENT

WHEREAS, WE, Martin L. Bryant, Gilles Gosselin, and Jean-Louis Imbach have invented certain improvements in "3'Prodrugs of 2'-Deoxy- β -L-Nucleosides" for which We/I have executed a United States Provisional Application No. 60/212,100 on June 15, 2000 and a non-provisional application on June 15, 2001 and


WHEREAS, Centre National Da La Recherche Scientifique (CNRS), a public agency operating under the supervisory authority of France's Ministry of Research and Technology, located at 3, Rue Michel-ange 75794, Paris, cedex 16, France desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by Centre National Da La Recherche Scientifique (CNRS), the receipt and sufficiency of which are hereby acknowledged, I, Gilles Gosselin, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto Centre National Da La Recherche Scientifique (CNRS), in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 16th day of
July, 2001.



Gilles Gosselin



Witness
Bergogne Marie-Christine

ASSIGNMENT

WHEREAS, WE, Martin L. Bryant, Gilles Gosselin, and Jean-Louis Imbach have invented certain improvements in "3'Prodrugs of 2'-Deoxy- β -L-Nucleosides" for which We/I have executed a United States Provisional Application No. 60/212,100 on June 15, 2000 and a non-provisional application on June 15, 2001 and


WHEREAS, Centre National Da La Recherche Scientifique (CNRS), a public agency operating under the supervisory authority of France's Ministry of Research and Technology, located at 3, Rue Michel-ange 75794, Paris, cedex 16, France desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by Centre National Da La Recherche Scientifique (CNRS), the receipt and sufficiency of which are hereby acknowledged, I, Jean-Louis Imbach, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto Centre National Da La Recherche Scientifique (CNRS), in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 17 day of
July, 2001.



Jean-Louis Imbach



Witness
Berigogne Marie-Christine

ASSIGNMENT


WHEREAS, WE, Martin L. Bryant, Gilles Gosselin, and Jean-Louis Imbach have invented certain improvements in "3'Prodrugs of 2'-Deoxy- β -L-Nucleosides" for which We/I have executed a United States Provisional Application No. 60/212,100 on June 15, 2000 and a non-provisional application on June 15, 2001 and

WHEREAS, NOVIRIO PHARMACEUTICALS LIMITED, a Cayman Island corporation having an office at c/o Walker Secretaries, Walker House, Mary Street, Grand Cayman, Cayman Islands desires to purchase same;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by NOVIRIO PHARMACEUTICALS LIMITED, the receipt and sufficiency of which are hereby acknowledged, I, Martin L. Bryant, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto NOVIRIO PHARMACEUTICALS LIMITED, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 16 day of

July, 2001.



Martin L. Bryant

On this 16 day of July, 2001, before me, a notary public, came Martin L. Bryant to me known and known to be the individual described in and who executed the foregoing assignment, and he duly acknowledged the same to be his free act and deed.



Notary Public


(SEAL)

My commission expires: CYNTHIA B. GAGNE
Notary Public
My Comm. Expires Sept. 25, 2003

06171.105012

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that the enclosed Recordation of Assignment, along with any paper referred to as being attached or enclosed, is being deposited with the United States Mail on the date shown below with sufficient first-class postage in an envelope to Box Assignment, Assistant Commissioner for Patents, Washington, DC 20231.



Sally Sexton

Date: September 10, 2001



UNITED STATES
PATENT AND
TRADEMARK OFFICE

06171405026

AUGUST 08, 2002

PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

KING & SPALDING
SHERRY M. KNOWLES
45TH FLOOR, 191 PEACHTREE STREET, N.E.
ATLANTA, GA 30303



102119575A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/06/2002

REEL/FRAME: 012962/0712
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE (CNRS)

DOC DATE: 04/19/2002


ASSIGNEE:

L'UNIVERSITE MONTPELLIER II (UMII)
2 PLACE EUGENE BATAILLON 34095
MONTPELLIER CEDEX 5, FRANCE

SERIAL NUMBER: 09883033
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

LAZENA MARTIN, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



06-11-2002

Form PTO-1595 (Adapted)
3-13-96

102119575

U.S. DEPARTMENT OF COMMERCE
U.S. Patent & Trademark Office**RECORDATION FORM COVER SHEET**
PATENTS ONLY

To the Honorable Commissioner for Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): 6.6.02 Centre National De La Recherche Scientifique (CNRS) Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): Name: L' Université Montpellier II (UMII) Address: 2 place Eugène Bataillon 34095 City, State, Zip Montpellier Cedex 5, France
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment NOTE: This Assignment conveys only the rights received from Jean-Louis Imbach and is being submitted in English & French along with Attachment A Execution Date: April 19, 2002	Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
4(a). Patent Application No.(s): 09/883,033 4(b). Patent No.(s): _____ If this document is being filed together with a new application, the execution date of the application is: Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Sherry M. Knowles Address: KING & SPALDING 45th Floor, 191 Peachtree Street, N.E. Atlanta, Georgia 30303	6. Total number of applications and patents involved: 1 7. Total fee (37 CFR 3.41) enclosed: \$ 40.00

DO NOT USE THIS SPACE**8. Statement**

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Certificate of Mailing and Signature

I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date given below.

Josephine Young

Name of Person Signing

Signature

5/24/02

Date

Attorney Docket No: **06171.105012 (NOV 1005)**Total number of pages including cover sheet: **7**

Mail documents to be recorded with required cover sheet information to:

 Commissioner for Patents
 Box Assignments
 Washington, DC 20231

06/12/2002 LMUELLER 00000063 09883033

01 FC:581

40.00 DP

ASSIGNMENT

THIS ASSIGNMENT, made by Centre National De La Recherche Scientifique (CNRS), a public agency operating under the supervisory authority of France's Ministry of Research and Technology, located at 3, Rue Michel-Ange 75794, Paris, Cedex 16, France, assigns to the L'Université Montpellier II (UMII), a Public Institution with cultural and professional vocation, located at 2 place Eugène Bataillon 34095 Montpellier Cedex 5, all rights received by CNRS from Jean-Louis Imbach by written assignment to the patents and patent applications listed in Attachment A. For avoidance of doubt, it is confirmed that this Assignment does not convey any of the ownership rights of CNRS arising out of the work of Dr. Gilles Gosselin in the patents and patent applications listed in Attachment A, and that the CNRS remains a co-assignee of all of the patents and patent applications listed in Attachment A by virtue of its ownership rights flowing from the work of Dr. Gilles Gosselin.


NOW, THEREFORE, To All Whom It May Concern, be it known that and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the above Assignor has sold and by these presents does hereby sell, assign, transfer and convey unto the said Assignee, and assigns the full title and interest of Jean-Louis Imbach in and to said Patents, in the inventions represented thereby and any and all reissues, renewals, divisions, continuations, and any other applications that claim priority thereto or from which these applications claim priority, letters Patent or continuations-in-part thereof; or any foreign counterpart thereof, and which may be granted therefor or thereon, for the full end of term for which said Letters Patent may be granted, and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

From time to time after the date hereof, at the request of either party hereto, and at the expense of the party so requesting, each of the parties hereto shall execute and deliver to such requesting party such documents and take such other action as such requesting party may reasonably request in order to consummate more effectively the transactions contemplated hereby.

The Assignor further covenants and agrees that, at the time of the execution and delivery of these presents, it possesses full title to the inventions and Patents thereon as earlier identified, and that it has the unencumbered right and authority to make this assignment.

This Assignment has been drafted in the English and French language. In case of contradiction between the two versions, the French language document will prevail.

Centre National de La Recherche Scientifique
Assignor

By Pour le Directeur Général
et par Délégué
Title Le Délégué aux Entreprises par Intérim

Joseph BAXERAS

CESSION

Par le présent contrat, le Centre National de la Recherche Scientifique (CNRS), établissement public agissant sous la tutelle du Ministre français chargé de la Recherche, situé au 3, Rue Michel-Ange, 75794, Paris Cedex 16, France, fait cession à l'Université Montpellier II (UMII), établissement public à caractère scientifique, culturel et professionnel, situé 2 place Eugène Bataillon, 34095 Montpellier Cedex 5, de l'ensemble des droits transférés par Monsieur Jean-Louis Imbach au CNRS en vertu d'un contrat de cession écrit, et afférents aux brevets et aux demandes de brevets listés à l'Annexe A. Il est précisé et confirmé que la présente cession ne porte aucunement sur les droits de propriété du CNRS résultant des travaux menés par le Docteur Gilles Gosselin dans les brevets et les demandes de brevets listés à l'Annexe A, et que le CNRS demeure co-cessionnaire de l'ensemble des brevets et demandes de brevets listés à l'Annexe A en vertu des droits de propriété générés par les travaux du Docteur Gilles Gosselin.

En conséquence de quoi, le Cédant ci-dessus mentionné a cédé et par les présentes cède et transfère au Cessionnaire ci-dessus mentionné l'intégralité des droits de propriété et de jouissance détenus par Monsieur Jean-Louis Imbach sur les dits Brevets, sur les inventions qu'ils représentent, et sur toute délivrance ("*reissues*"), tout renouvellement, tout divisionnaire, toute extension ("*continuation*") et toute autre demande revendiquant priorité sur ceux-ci ou dont la priorité est revendiquée sur ceux-ci, les brevets d'invention ("*letters Patent*") ou leurs "*continuations-in-part*", ou les titres correspondants étrangers, qui peuvent être consentis pour eux ou sur eux, pour toute la durée entière pour laquelle les dits brevets d'invention ("*Letters Patent*") peuvent être consentis, et toutes les demandes, requêtes, déclarations sous serment et cessions ou tout autre document ou acte qui peut être requis aux fins de donner plein effet à la cession et au transfert auquel il est procédé par les présentes ou auquel les parties ont souhaité procéder.

De temps en temps, postérieurement à la date des présentes, à la demande de l'une ou l'autre des parties au présent contrat, et aux frais de la partie requérante, chacune des parties au présent contrat signera et transmettra à la partie requérante les documents et entreprendra toute autre action que la partie requérante pourra raisonnablement demander aux fins de parfaire les effets des transactions visées par le présent contrat.

Le Cédant déclare et garantit qu'à la date de la signature du présent contrat et de son enregistrement, il est titulaire de l'intégralité des droits sur les inventions et les Brevets délivrés sur lesdites inventions, telles qu'identifiés ci-avant, que les dites inventions et Brevets n'ont fait l'objet d'aucun gage et nantissement, et qu'il a tout pouvoir pour procéder à la présente cession.

Le présent contrat de cession a été rédigé en anglais et en français. En cas de contradiction entre les deux versions, la version française prévaudra.

Le Centre National de La Recherche Scientifique
Le Cédant

Par _____


Titre _____
Pour le Directeur Général
et par Délégué
Le Délégué aux Entreprises par Intérim
Joseph BAIXERAS

Attachment A

TITLE & DOCKET NAME	COUNTRY	FILING DATE	INVENTORS	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
NOV/1000 Provisional β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S. CON	8/10/98 04/28/99	Gilles Gosselin Jean-Louis Imbach	60096,110 60/131,352		
NOV/1000 Normal β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	Gilles Gosselin Jean-Louis Imbach Martin L. Bryant	09/371,747	6,395,716	5-28-02
NOV/1000 CON β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	Gilles Gosselin Jean-Louis Imbach Martin L. Bryant	10/022,276		
NOV/1000 CIP β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	Gilles Gosselin Jean-Louis Imbach Martin L. Bryant	09/459,150		
NOV/1000 CIP CON β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	Gilles Gosselin Jean-Louis Imbach Martin L. Bryant	10/022,148		
NOV/1000 PCT β-L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	PCT	8/10/99	Gilles Gosselin Jean-Louis Imbach Martin Bryant	PCT/US99/18149	WO 00/09531	2/24/00
	Australia	8/10/99		54757/99		
	Brazil	8/10/99		99/12896-9		
	Canada	8/10/99		2,340,156		
	China	8/10/99		99809553.2 CNI320128A		

16

TITLE & DOCKET NAME	COUNTRY	FILING DATE	INVENTORS	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
	Bmore	8/10/99		99941027.7 1104436 A	1104436 A	
	Hong Kong	8/10/99		01104418.5 1034083		
	India	8/10/99		IN/PCT/2001/ 00194/DEL		
	India DIV I	8/10/99		IN/PCT/2001/ 00465/DEL		
	Japan	8/10/99		2000-564981		
	S. Korea	8/10/99		2001-7001758		
	Mexico	8/10/99		1001507		
	Russian Federation	8/10/99		2001106651		
	Singapore	8/10/99		200102730-9		
NOV 1005 3'-Prodrugs of 2'-deoxy-β-L- Nucleosides	U.S. Prov.	6/15/00	Martin L. Bryant; Gilles Gosselin Jean-Louis Imbach	60212,100		
	U.S.	6/15/01		09/883,033		
	PER	6/15/01		US01/19147		
	Argentina	6/15/01		010102881		
	Bolivia	6/15/01		007456		
	Chile	6/15/01		1381-2001		
	Egypt	11/4/01		1168/2001		
	Malaysia	6/15/01		PD0012807		
	Pakistan	6/15/01		552/2001		
	Paraguay	6/15/01		N/A		
	Peru	6/15/01		584/2001		
	Philippines	6/15/01		2001-01499		
	Uruguay	6/15/01		26.779		
	Venezuela	6/15/01		1265-2001		
	Taiwan	6/15/01		90114380		
	Thailand	6/15/01		066273		



OCTOBER 28, 2002

PTAS

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov



102199601A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/19/2002

REEL/FRAME: 013193/0841
NUMBER OF PAGES: 4

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/28/2002

ASSIGNEE:
IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60132126
PATENT NUMBER:

FILING DATE: 04/30/1999
ISSUE DATE:

SERIAL NUMBER: 60096110
PATENT NUMBER:


FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276
PATENT NUMBER:

FILING DATE: 12/14/2001
ISSUE DATE:



SERIAL NUMBER: 09459150
PATENT NUMBER: 6444652

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

SERIAL NUMBER: 10022148
PATENT NUMBER:

FILING DATE: 12/14/2001
ISSUE DATE:

SERIAL NUMBER: 09744038
PATENT NUMBER:

FILING DATE: 05/01/2001
ISSUE DATE:

SERIAL NUMBER: 60207538
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 09867110
PATENT NUMBER:

FILING DATE: 05/29/2001
ISSUE DATE:

SERIAL NUMBER: 60212100
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

SERIAL NUMBER: 60207674
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 60283276
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 09863816
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60206585
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:

SERIAL NUMBER: 09864078
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60283393
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 10122252
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

SERIAL NUMBER: 60249532
PATENT NUMBER:

FILING DATE: 11/17/2000
ISSUE DATE:

SERIAL NUMBER: 10001868
PATENT NUMBER:

FILING DATE: 11/19/2001
ISSUE DATE:

SERIAL NUMBER: 60326184
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 60326192
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

013193/0841 PAGE 3

SERIAL NUMBER: 09371747
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002

PAULA MCCRAY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

08-22-2002



102199601

FORM-PTO-1595
1-31-92TRANSMITTAL OF DOCUMENTS
PATENTS ONLY

RDATION

Atty. Docket 06171.105004

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Novirio Pharmaceuticals Limited *08/19/02*
 Additional name(s) of conveying party(ies) attached?
☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Idenix Pharmaceuticals Inc.

Foreign Address:

Domestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☐ Yes ☒ No

3. Nature of Conveyance:

☐ Assignment ☐ Merger
☐ Security Agreement ☒ Change of Name
 Other _____

Execution Date: 5/28/02

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) see attached

B Patent Registration No. (s)

Additional numbers attached? ☒ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-51006. Number of applications and patents involved:
237. Total fee (37 CFR 3.41): \$ 920☒ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.

Sally Sexton

Name of Person Signing

Sally Sexton
SignatureAugust 13, 2002

Date

Total number of pages comprising cover sheet: 13


08/21/2002 TDIAZ1 00000095 60132126

01 FC:581

920.00 OP

CR-81404

Certificate of Incorporation On Change Of Name



I DO HEREBY CERTIFY that

NOVIRIO PHARMACEUTICALS LIMITED

having by Special Resolution dated 28th of May 2002 changed its name, is now incorporated under the name of

Idenix Pharmaceuticals, Inc.

Given under my hand and Seal at George Town in the Islands of Grand-Cayman this Twenty-Eighth day of May Two Thousand Two
(SIGNED, H. DIXON)

CERTIFIED TO BE A TRUE AND CORRECT COPY

SIG. WILL H. DIXON
Asst. Registrar of Companies

Date 28th May, 2002

CERTIFIED TRUE COPY

WALKERS
ATTORNEYS-AT-LAW
WALKER HOUSE, GEORGE TOWN
GRAND CAYMAN, CAYMAN ISLANDS

DATE: 5/7/2002


Schedule

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX 1001: Provisional Use of 3'-Azido-2',3'- Dideoxyuridine	U.S.	04/30/99	60/132,126		
IDX 1000 Provisional β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/98	60/096,110		
	CON	04/28/99	60/131,352		
IDX 1000 Normal β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	09/371,747	6,395,716	5/28/02
IDX 1000CON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,276		
IDX/1000 CIP β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	09/459,150		
IDX 1000 CIPCON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,148		
IDX 1003 Substituted 6-Benzyl-4- Oxypyrimidines, Process for Their Preparation and Pharmaceutical Compositions Containing Them	US	07/17/99	09/744,038		
IDX 1004 Methods for Treating Hepatitis Delta Virus Infection with β - L-2' Deoxy-Nucleosides	U.S. Prov.	5/29/00	60/207,538		
	U.S.	5/29/01	09/867,110		
IDX 1005 3'-Prodrugs of 2' deoxy- β -L- Nucleosides	U.S. Prov.	6/15/00	60/212,100		
	U.S.		09/883,033		
IDX1006 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	5/26/00 4/11/01	60/207,674 60/283,276		
	U.S.	5/26/01	09/863,816		

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX1007 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	05/23/00	60/206,585		
	U.S.	05/23/01	09/864,078		
IDX1008 Phenylindoles For The Treatment Of HIV	U.S. Prov.	4/11/01	60/283,393		
	U.S.	4/11/02	10/122,252		
IDX1009 Methods for Inhibiting the Transmission of HIV Using Topically Applied Substituted 6-Benzyl-4-Oxopyrimidines	U.S. Prov.	11/17/00	60/249,532		
	U.S.	11/19/01	10/001,868		
IDX1013 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	9/28/01	60/326,184		
IDX1014 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	9/28/01	60/326,192		

CERTIFICATE OF MAILING (37 CFR § 1.8a)

I hereby certify that this Recordation of Assignment, along with any other paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Box Assignment, Assistant Commissioner for Patents, Washington, D.C. 20231.


Sally Sexton

06171.105004

Date: August 13, 2002



UNITED STATES
PATENT AND
TRADEMARK OFFICE

JUNE 11, 2003

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



102359457A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/06/2003

REEL/FRAME: 013718/0543
NUMBER OF PAGES: 7

BRIEF: CERTIFICATE OF DOMESTICATION INCORPORATION IN DELAWARE

ASSIGNOR:

NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/30/2002

ASSIGNEE:

IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60096110 - 105002
PATENT NUMBER:

FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352 - 105002
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276 - 105080
PATENT NUMBER: 6569837

FILING DATE: 12/14/2001
ISSUE DATE: 05/27/2003

SERIAL NUMBER: 10022148 10x1000
PATENT NUMBER: 6566344

FILING DATE: 12/14/2001
ISSUE DATE: 05/20/2003

VDH Rec'd

JUN 17 2003

SERIAL NUMBER: 60207538 - 105011
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 09867110 - 105021
PATENT NUMBER:

FILING DATE: 05/29/2001
ISSUE DATE:

SERIAL NUMBER: 60212100 - 105012
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033 - 105026
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

SERIAL NUMBER: 60207674 - 105008
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 60283276 - 105008
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 09863816 - 105027
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60206585 - 105009
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:

SERIAL NUMBER: 09864078 - 105022
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60283393 - 105013
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 10122252 - 105033
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

SERIAL NUMBER: 60249532 - 105014
PATENT NUMBER:

FILING DATE: 11/17/2000
ISSUE DATE:

SERIAL NUMBER: 10001868 - 105030
PATENT NUMBER: 6545007

FILING DATE: 11/19/2001
ISSUE DATE: 04/08/2003

SERIAL NUMBER: 60326184 - 105018
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 60326192 - 105020
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 09371747 - 105005
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002


SERIAL NUMBER: 09459150 - 105007
PATENT NUMBER: 6444652

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

013718/0543 PAGE 3

SAUNDRA BALLENGER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

02-07-2003



102359457

FORM-PTO-1595
1-31-92TRANSMITTAL OF DOCUMENT FOR RECORDATION
PATENTS ONLYAtty. Docket 06171.105094 ²

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Novirio Pharmaceuticals Limited **2-6-03**
Additional name(s) of conveying party(ies) attached?
☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Idenix Pharmaceuticals Inc.

Foreign Address:

Domestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☐ Yes ☒ No

3. Nature of Conveyance:

- ☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☒ Other Certificate of Domestication;

incorporation in DelawareExecution Date: 5/30/02

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B Patent Registration No. (s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-51006. Number of applications and patents involved:
227. Total fee (37 CFR 3.41): \$ 880☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

OFFICE OF PUBLIC RECORDS

FINANCE SECTION

2003 FEB - 6 PM 3:03

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.

Sally Sexton

Name of Person Signing

Sally Sexton
Signature

January 30, 2003

Date

Total number of pages comprising cover sheet: 3

02/07/2003 EDOOPER 00000082 600%110

01 FC:8021


880.00 CP

CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002



Jean Pierre Sommadossi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

FROM

(THU) 5.30'02 7:59/ST.

STATE OF DELAWARE
DIVISION OF CORPORATIONS
FILED 08:00 AM 05/30/2002
020342271 - 3530324

**CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.**

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002

/s/ Jean-Pierre Sommadossi
Jean Pierre-Sommadosi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

Idenix Pharmaceuticals Patent Docket

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX 1000 Provisional β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/98	60/096,110		
	CON	04/28/99	60/131,352		
IDX 1000 Normal β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	09/371,747	6,395,716	5/28/02
IDX 1000CON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,276		
IDX/1000 CIP β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	09/459,150	6,444,652	9/3/02
IDX 1000 CIPCON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,148		
IDX 1004 Methods for Treating Hepatitis Delta Virus Infection with β - L-2' Deoxy-Nucleosides	U.S. Prov.	5/29/00	60/207,538		
	U.S.	5/29/01	09/867,110		
IDX 1005 3'-Prodrugs of 2'-deoxy- β -L- Nucleosides	U.S. Prov.	6/15/00	60/212,100		
	U.S.		09/883,033		
IDX1006 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	5/26/00 4/11/01	60/207,674 60/283,276		
	U.S.	5/26/01	09/863,816		
IDX1007 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	05/23/00	60/206,585		
	U.S.	05/23/01	09/864,078		
IDX1008 Phenylindoles For The Treatment Of HIV	U.S. Prov.	4/11/01	60/283,393		
	U.S.	4/11/02	10/122,252		

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX1009 Methods for Inhibiting the Transmission of HIV Using Topically Applied Substituted 6-Benzyl-4- Oxopyrimidines	U.S. Prov.	11/17/00	60/249,532		
	U.S.	11/19/01	10/001,868		
IDX1013 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	9/28/01	60/326,184		
IDX1014 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	9/28/01	60/326,192		

Registrar of Companies,
Tower Building,
Grand Cayman.

Dear Sir,

IDENIX PHARMACEUTICALS, INC.

I, Andrea J. Corcoran, of 61 Garfield Street, Cambridge, MA 0218, being a director of Idenix Pharmaceuticals, Inc. (the "Company"), an exempted company incorporated under the Companies Law (2001 Second Revision), DO HEREBY make application, pursuant to Section 226 of the Companies Law (2001 Second Revision) for the Company to be deregistered in the Cayman Islands.

In support of this application:

1. I would advise that the Company has been accepted for domestication pursuant to Section 388 of the General Corporation Law of the State of Delaware, the United States of America. A copy of the Certificate of Domestication is attached to this application. I confirm that the laws of the State of Delaware, the United States of America permit the transfer of the Company to that jurisdiction and indeed that is the effect of the domestication procedure.
2. I enclose payment of US\$2,414.63 (CIS1980) in respect of the fee for deregistration.
3. I confirm that the Company does not propose to change its name following deregistration.
4. I confirm that the Company has no secured creditors.
5. I confirm that the Company is not and has never been licensed under the provisions of the Banks and Trust Companies Law, (2001 Revision) or the Insurance Law, (2001 Revision).

I attach to this application

1. a certified copy of the Special Resolution of the Company adopted on ___ May 2002 resolving to register the Company by way of continuation in the State of Delaware, the United States of America;
2. a certified copy of the Resolution adopted by the Board of Directors of the Company dated May 6, 2002 resolving to apply for deregistration pursuant to Section 226 of the Companies Law (2001 Second Revision) and authorising me to make this application on behalf of the Company; and
3. my affidavit in support of this application in the terms prescribed by section 226(3) of the Companies Law (2001 Second Revision).

DATED this day of May 2002


Andrea J. Corcoran

Director

IDENIX PHARMACEUTICALS, INC.

Delaware


PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DOMESTICATION OF "IDENIX PHARMACEUTICALS, INC.", FILED IN THIS OFFICE THE THIRTIETH DAY OF MAY, A.D. 2002, AT 8 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF DOMESTICATION IS THE THIRTIETH DAY OF MAY, A.D. 2002, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3530324 8100D


AUTHENTICATION: 1802262

020342271

DATE: 05-30-02

CERTIFICATE OF MAILING (37 CFR § 1.8a)

I hereby certify that this Recordation of Assignment, along with any other paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Box Assignment, Commissioner for Patents, Washington, D.C. 20231.



Sally Sexton

06171.105004
Date: January 30, 2003